Objective: Most prolactinomas in females are diagnosed during the reproductive age, and the majority are microadenomas. Prolactinomas detected in the postmenopausal period are less common with limited published data on their presentation and prognosis. Our objective was to assess the presenting clinical, biochemical and imaging findings, as well as the outcomes of women diagnosed with a prolactinoma in the postmenopausal period.
PRL-secretory granules; all these effects are reversed by oestradiol. 5 Interestingly, in vivo oestrogen administration induces lactotroph tumours in rats, 6 and selective anti-oestrogen treatment inhibits lactotroph tumour growth in rats harbouring subcutaneous implanted PRL-secreting pituitary tumours. 7 Although a number of studies in humans do not support an association between use of oral contraceptives or oestrogen replacement therapy and prolactinoma formation or growth in women (at least in microadenomas), these adenomas may enlarge during pregnancy, and cases of prolactinomas occurring after long-term oestrogen therapy in male-female transsexuals have been reported. 8, 9 Menopause, a physiological state of hypo-oestrogenism,
can have a beneficial effect on the natural history of hyperprolactinaemia. A small number of studies have shown that long-term reduction or normalization of PRL in women with microprolactinoma after the cessation of their menses can occur, 10, 11 and therefore stopping treatment with dopamine agonist may be a justified approach.
Females diagnosed with a prolactinoma in the postmenopausal period represent a less common and possibly under-recognized group, as the compromised ovarian function alters the presenting clinical manifestations, and the changes in the oestrogen status may have an impact on the natural history of the tumour. In fact, epidemiological studies report standardized incidence rates of around 1/100 000 for prolactinomas diagnosed in females aged above 50 years. 2, 3 As a result of this, data on their clinical phenotype, natural history and outcomes are extremely limited, with only a single report published to date
;
this involved a case series of 14 patients from three different endocrine outpatient clinics in three academic centres from Israel, USA and Brazil. Therefore, and taking into account the reported impact of menopause on PRL secretion, studies providing further insight into this specific group of patients would be of value in clinical practice.
The aim of our study was to assess the clinical, biochemical and imaging findings at presentation and during follow-up, as well as the outcomes of women diagnosed with a prolactinoma during the postmenopausal period and managed in a single pituitary centre in the UK.
| PATIENTS AND METHODS

| Patients
All females with a prolactinoma diagnosed in the postmenopausal period (mean age of menopause in the UK 51 years) and reviewed in the In cases in which dopamine agonist therapy was offered, the dose was gradually titrated until achievement of normal PRL or until maximum tolerated dose was achieved. Pituitary imaging was performed within 6 months after starting treatment and at clinically indicated intervals thereafter. The assessment of visual fields was performed by Goldmann perimetry.
The study was completely retrospective in nature and involved no intervention beyond routine patient care. It was registered with and approved as an audit by the University Hospitals Birmingham NHS Foundation Trust.
| Prolactin assay
The 
| Statistics
Percentages were calculated for categorical data and medians with ranges for continuous variables. Correlation between age and PRL levels at diagnosis was performed by the Pearson's correlation method. In terms of menstrual history, five women had a history of amenorrhoea for which they had no investigations during the reproductive age; their prolactinoma was diagnosed at the ages of 52, 60, 63, 65
and 66 years; two had hysterectomy at the age of 29 and 34 and were
T A B L E 1 Presenting clinical, biochemical and imaging manifestations of the women with prolactinoma diagnosed in the postmenopausal period
No. T A B L E 1 (Continued) leading to diagnosis of the tumour. Thus, the sequelae of hyperprolactinaemia are not evident (apart from the rare cases of galactorrhoea), and the consequences of a pituitary mass lesion, headaches and/or visual disturbances, are the most common presenting manifestations (47% in our series). Interestingly, two cases (12%) were diagnosed incidentally and involved adenomas with PRL of 9046 and 11 401 mU/L, respectively, and minimal or no suprasellar extension. It is also of note that five women had a history of long-standing amenorrhoea for which no investigations had been carried out during reproductive age; their macroadenoma was diagnosed between the ages of 52 and 66 years. Although these may not relate with the prolactinoma, the long-standing presence of the tumour cannot be excluded, reflecting the natural history of untreated prolactinoma.
Age at
Interestingly, pituitary apoplexy was the first presentation in two of our patients. Although extracted from a small number of cases, this percentage is remarkable compared with the reported apoplexy rate of 0.81% in a series of 368 prolactinomas treated in a single centre during a period of 11 years (upper interquartile range for age at diagnosis in females and males: 37 and 54.5 years, respectively). 13 In the same paper, macroadenoma and female gender were strongly predictive of the presence of pituitary haemorrhage (not necessarily associated with clinical picture of apoplexy) on MRI. 13 A rapidly expanding adenoma that outstrips its blood supply and results in ischaemia/haemorrhagic infarction, as well as compression of the pituitary vessels at the diaphragmatic notch has been proposed as potential mechanisms. 13, 14 In our study, pituitary apoplexy was diagnosed in a third patient 8 months after starting cabergoline. This necessitated transsphenoidal surgery due to visual deterioration; cabergoline was subsequently restarted with no further apoplectic event as of latest assessment. Cases of patients with pituitary apoplexy whilst on dopamine agonist have been previously described
15
; a potential causal link and the mechanism of this remain to be clarified. Overall, the rate of apoplexy in our patient group was 18%. It is of note that in epidemiological studies looking at the prevalence of prolactinomas, the overall rates of apoplexy range between 0% and 2.7%. [1] [2] [3] Whether postmenopausal women with prolactinoma are predisposed to pituitary apoplexy, or whether our finding is a mere coincidence remains to be elucidated.
It has been previously suggested that PRL levels usually reflect tumour size. 16 We attempted to clarify whether PRL values also correlate with age at diagnosis in the group of postmenopausal women but our analysis did not support this.
We found that 94% of the prolactinomas were macroadenomas with often invasive behaviour; supra/parasellar extension was detected in 88% of the tumours. This is in contrast to the imaging features seen in premenopausal females, where the majority are microadenomas: 70% in a series of 51 females aged at diagnosis 28±1 years 16 and 85% in a series of 325 females with median age at diagnosis of 31 years (interquartile range 25-37). 13 However, the true prevalence of microprolactinomas in postmenopausal women is difficult to ascertain, as the manifestations of hyperprolactinaemia are usually not clinically relevant, and possibly, a number of postmenopausal females harbouring this type of tumour escape diagnosis. In fact, in a meta-analysis, the prevalence of pituitary adenoma from autopsy studies was 14.4% and, when immunohistochemical staining took place, PRL-positive cells were identified in 25%-41% of the specimens, indicating that a significant number of prolactinomas may not be diagnosed during the lifespan. 17 Published literature suggests that in males, prolactinomas are diagnosed at an older age, and as in the postmenopausal women, there is a predominance of large and often invasive tumours (63%-89% being macroadenomas). 2, 3, 16, 18, 19 Although not widely accepted, 20 this may be attributed to a true gender difference in adenoma behaviour with higher proliferative activity in males. 16 It should be noted, however, that bias related with the selection and study of surgically-only managed tumours may influence the validity of these reports.
In our series, we did not confirm aggressive adenoma behaviour in postmenopausal women; treatment with dopamine agonists led to normal PRL and to tumour shrinkage in 94% and 100% of the macroprolactinomas, respectively. Previous studies including both males and females of all ages with macroprolactinoma showed that cabergoline led to normoprolactinaemia in 61%-89% and tumour shrinkage (using various criteria) in 55%-73% of cases. The published literature on prolactinomas detected after menopause is limited with only one report published of a case series from three different endocrine outpatient clinics in three academic centres from Israel, USA and Brazil. 12 They authors identified 14 women who were diagnosed with a prolactinoma after menopause; 5 of 14 (36%) had no specific complaints when diagnosed, 6 of 14 (43%) had reported headaches and/or visual disturbances, 2 of 14 (14%) had galactorrhoea and 1 (7%) had diplopia. Similar to our study, 93% had macroadenomas; suprasellar extension was seen in 57% and visual field defects were detected in 43%. Median PRL was 827 ng/mL (17 532 mU/L, range 85-6732 ng/mL). Cabergoline was offered to 12 patients who were followed up for a median period of 66 months;
in agreement with our results, optimal response was seen with PRL normalization in 10 (83%) and reduction in adenoma size (of various degrees) in 11 (92%) of cases.
A potential limitation of our study is the lack of data on adenoma behaviour after stopping the dopamine agonist treatment in this age group. Collaborative studies would be required to reliably address this question, and also to clarify the natural history of prolactinomas diagnosed after menopause and not treated with dopamine agonists (due to lack of pressure effects). The advantage of our study is the inclusion of a large number of cases, which were also nonselected, consecutive and with detailed clinical characterization, managed with a similar approach in a single centre.
In conclusion, the clinical phenotype of prolactinomas detected in the postmenopausal period differs from that of premenopausal women. Macroadenomas with often invasive behaviour dominate, and the mass effect leads to most of the signs and symptoms that prompt investigations and diagnosis. The rate of pituitary apoplexy was high in our series, and this, although requiring further confirmation, needs to be kept in mind. Nonetheless, it is very reassuring to confirm that medical treatment is highly effective in this group of patients.
